Pain relief injection before breast surgery for triple-negative cancer
Part of Cancer, Skin clinical trials.
This trial tests whether injecting a numbing medicine around the tumor and nearby nerves before breast-conserving surgery can reduce pain and improve recovery for women with triple-negative breast cancer who have already had chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman with triple-negative breast cancer confirmed by biopsy.
- You have already completed chemotherapy before surgery.
- You are scheduled for breast-conserving surgery (lumpectomy) with sentinel node biopsy or lymph node removal, under general anesthesia.
- You are generally healthy (able to do daily activities; ECOG score 0 or 1).
- You are an adult (of legal age) and agree to participate.
- You are not allergic to local anesthetics and do not have metastatic breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests whether giving a targeted drug before surgery can help shrink early-stage triple-negative breast cancer tumors. It may be an option for people who have not yet had any treatment for their breast cancer.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.